• Global Q3 sales up 16% to AUD$1.5 million
• Australia Q3 sales up 15% to AUD$0.9 million
• Canada Q3 sales up >100% to AUD$0.1 million

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, has announced continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. Global Q3 sales were AUD$1.5 million, up 16% on the prior comparative period (pcp). Year-to-date March 2026 sales were AUD$5.7 million, up 7% on pcp. In Australia, Q3 sales were AUD$0.9 million, up 15% on pcp, while year-to-date March 2026 sales were AUD$4.2 million, up 14% on pcp. In Canada, Q3 sales were AUD$0.1 million, up over 100% on pcp, with a 82% increase on the prior quarter, driven by initial sales to the leading pharmacy group Jean Coutu in Quebec. U.S. Q3 sales were AUD$0.5 million, up 1% on pcp. The company attributed the sales growth to increased brand awareness and consumer promotions, as well as new store listings and increased travel in key markets.